Tonix Starts Phase 1 Trial for New Migraine Pain Treatment
Tonix Pharmaceuticals has dosed the first participant in an investigator-initiated Phase 1 study of TNX-1900, an intranasal, magnesium-potentiated oxytocin...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Tonix Pharmaceuticals has dosed the first participant in an investigator-initiated Phase 1 study of TNX-1900, an intranasal, magnesium-potentiated oxytocin...
ORIC will detail combination dose optimization findings from its Phase 1b study of rinzimetostat (ORIC-944) in metastatic castration-resistant prostate...
The POLAR trial's Phase 2 results in homologous-recombination-deficient metastatic pancreatic cancer aren't just a clinical win — they're an...
Glucotrack’s first-in-human study of its fully implantable continuous blood glucose monitor reported a Mean Absolute Relative Difference of 7.7%...
Radiopharm Theranostics has dosed the first patient in its first-in-human Phase 1 trial of RAD 402 in advanced prostate...
Litifilimab achieved clear or almost clear skin in 14.7% of patients at Week 16 versus 2.9% on placebo in...
In the Phase 3 VALOR trial (n=241), brepocitinib 30 mg once-daily delivered a 15.3-point greater improvement in mean Total...
At Week 40 in the Phase 3 VELA program for moderate-to-severe hidradenitis suppurativa (HS), sonelokimab achieved a 62% HiSCR75...
Lilly and Novo have already won the weight-loss efficacy war. The next drug approval battle is being fought on...
In the Phase 3 Tigris trial of 157 adults with endotoxic septic shock, polymyxin B hemoadsorption (PMX) achieved a...